CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 1,666 shares at $24.30 ($40,484)
- 4 Planned sale Chief Medical Officer sold 2,768 shares at $23.79 ($65,851)
- 4 Open-market sale COFO and Secretary sold 2,772 shares at $23.67 ($65,613)
- 144 Insider Sale of Securities
- 4 Open-market sale President and CEO sold 2,526 shares at $25.03 ($63,226)
- 4 Open-market sale Chief Medical Officer sold 2,857 shares at $24.15 ($68,997)
- 4 Open-market sale COFO and Secretary sold 2,853 shares at $24.18 ($68,986)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale COFO and Secretary sold 19,702 shares at an average $29.80 ($587,157)
- 4 Planned sale Director sold 1,666 shares at $29.60 ($49,314)
Page 14 of 40 · 789 filings